- Home
- CRWD vs BMY Comparison
CRWD vs BMY Comparison
Compare CRWD & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRWD
- BMY
- Stock Information
- Founded
- CRWD 2011
- BMY 1887
- Country
- CRWD United States
- BMY United States
- Employees
- CRWD N/A
- BMY N/A
- Industry
- CRWD EDP Services
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- CRWD Technology
- BMY Health Care
- Exchange
- CRWD Nasdaq
- BMY Nasdaq
- Market Cap
- CRWD 103.5B
- BMY 94.0B
- IPO Year
- CRWD 2019
- BMY N/A
- Fundamental
- Price
- CRWD $509.19
- BMY $44.80
- Analyst Decision
- CRWD Buy
- BMY Hold
- Analyst Count
- CRWD 45
- BMY 15
- Target Price
- CRWD $485.93
- BMY $57.64
- AVG Volume (30 Days)
- CRWD 3.3M
- BMY 18.1M
- Earning Date
- CRWD 11-25-2025
- BMY 10-30-2025
- Dividend Yield
- CRWD N/A
- BMY 5.57%
- EPS Growth
- CRWD N/A
- BMY N/A
- EPS
- CRWD N/A
- BMY 2.49
- Revenue
- CRWD $4,341,102,000.00
- BMY $47,704,000,000.00
- Revenue This Year
- CRWD $23.43
- BMY N/A
- Revenue Next Year
- CRWD $21.89
- BMY N/A
- P/E Ratio
- CRWD N/A
- BMY $17.92
- Revenue Growth
- CRWD 23.46
- BMY 2.57
- 52 Week Low
- CRWD $286.78
- BMY $42.96
- 52 Week High
- CRWD $517.98
- BMY $63.33
- Technical
- Relative Strength Index (RSI)
- CRWD 64.84
- BMY 44.25
- Support Level
- CRWD $476.52
- BMY $44.25
- Resistance Level
- CRWD $503.50
- BMY $48.58
- Average True Range (ATR)
- CRWD 13.23
- BMY 1.14
- MACD
- CRWD 1.60
- BMY 0.03
- Stochastic Oscillator
- CRWD 93.69
- BMY 29.22
About CRWD CrowdStrike Holdings Inc.
CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.